Medtronic Cardiac Rhythm and Heart Failure
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Medtronic Cardiac Rhythm and Heart Failure sits in the top decile of US sponsors by registered trial count (#223 of 15,742 sponsors by registered trial count).
Medtronic Cardiac Rhythm and Heart Failure: 115 sponsored US clinical trials, 2 recruiting.
Medtronic Cardiac Rhythm and Heart Failure sponsors 115 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 100 completed. 6 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Heart Failure, with 10 trials.
Top-decile sponsor footprint
Medtronic Cardiac Rhythm and Heart Failure ranks in the top decile of sponsors by registered trial count (#223 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
100 of 109 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
115 total, page 2 of 3
REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)
NCT01574144
Cutaneous Heart Sounds Data Collection During Cardiac Resynchronization Therapy (CRT) Optimization Study
NCT01609985
Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure
NCT01486316
Acute Carotid Sinus Endovascular Stimulation II Study
NCT01458483
Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures
NCT01370564
Post-Myocardial Infarction Remodeling Prevention Therapy
NCT01213251
The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial
NCT01166347
Reveal In-Office Implants
NCT01168427
Advisa MRI Clinical Study
NCT01110915
Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure
NCT01112579
Feasibility Study of an Integrated Diagnostic System to Manage Heart Failure
NCT01045343
Attain Success Clinical Trial
NCT00990964
Adaptive Cardiac Resynchronization Therapy Study
NCT00980057
Extension Phase of the Chronicle® Offers Management to Patients With Advanced Signs & Symptoms of Heart Failure Study
NCT00991120
Safety and Clinical Performance of the Protecta ICD and CRT-D
NCT00982397
Optimize RV Follow-up Selective Site Pacing Clinical Trial
NCT00949715
Attain StarFix® 4195 Lead Extraction Study
NCT00893386
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
NCT00924638
Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming
NCT00856349
Continued Access Protocol
NCT00889681
Model 4396 Left Ventricular (LV) Lead Study
NCT00853593
OptiVol® Care Pathway
NCT00847288
Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
NCT00751972
ST Segment Detection Study
NCT00930969
Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure
NCT00510198
Tailored Treatment of Permanent Atrial Fibrillation
NCT00514735
EMRI SureScan™ Clinical Study
NCT00433654
Attain Model 4196 Left Ventricular (LV) Lead
NCT00271544
Optimize RV Selective Site Pacing Clinical Trial
NCT00422669
CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)
NCT00621621
CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision
NCT00402246
A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation
NCT00523978
D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management
NCT00328705
Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)
NCT00354159
Clinical Investigation of the Medtronic Concerto™ Device
NCT00268320
OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.
NCT00277524
IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
NCT00303979
Left Ventricular Capture Management (LVCM) Software Download Clinical Trial
NCT00268281
Managed Ventricular Pacing ("MVP") Trial
NCT00281099
REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
NCT00271154
Attain StarFix™ Model 4195 Left Ventricular Lead
NCT00269230
PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure
NCT00279955
Ensure Cardiac Resynchronization Therapy Study
NCT00291564
PREFER (Pacemaker Remote Follow-Up Evaluation and Review)
NCT00294645
Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG
NCT00273195
PROSPECT: Predictors of Response to Cardiac Re-Synchronization Therapy
NCT00253357
CAPTURE - Complete Automatic Pacing Threshold Utilization Recorded by EnPulse
NCT00275769
P3: Pacemaker Patient Profiling Study
NCT00294060
INSIGHTS ICD Registry
NCT00279968
Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)
NCT00289289
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 2 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the Medtronic Cardiac Rhythm and Heart Failure pipeline
2 recruiting of 115 indexed (2% open); 100 completed (87%).
Phase mix: 6 late (III/IV) vs 5 early (I/II) (balanced across stages).
Top condition: Heart Failure (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Medtronic Cardiac Rhythm and Heart Failure: open-pipeline peers nationwide
Peers matched on 115 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Medtronic Cardiac Rhythm and Heart Failure sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 115 trials (± recruiting share)
- Medstar Health Research Institute · 115 trials · 20% recruiting
- Zimmer Biomet · 115 trials · 10% recruiting
- Rockefeller University · 117 trials · 4% recruiting
- State University of New York - Upstate Medical University · 113 trials · 7% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Eisai · 2% recruiting · 287 trials
- Bausch & Lomb Incorporated · 2% recruiting · 174 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Medtronic Cardiac Rhythm and Heart Failure page
115 registered trials is a research-attention snapshot, not an endorsement of Medtronic Cardiac Rhythm and Heart Failure or any single study.
- 2 of Medtronic Cardiac Rhythm and Heart Failure's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Heart Failure is the condition Medtronic Cardiac Rhythm and Heart Failure studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Heart Failure trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Medtronic Cardiac Rhythm and Heart Failure pipeline card: 115 registered trials from official public datasets.Report a data error.